Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio
Agreement is part of Daiichi Sankyo’s five-year mid-term strategy to transform to a structure primarily…